Recce Ltd has released a press release.
Positive safety data from 4th Cohort -Phase I Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- $3.08m R&D Rebate Received
- Safety Committee Clears PhI R327 Dose Increase
- S&P DJI Announces March 2022 Quarterly Rebalance
- Positive Safety Continues in 3rd Cohort PhI Clinical Trial
- Positive Safety Data from Third Cohort of PI Clinical Trial
Later from Recce Pharmaceuticals
- Anti-Viral Patent Granted in Hong Kong
- Phase I Clinical Trial R327 Advances to High Dose Cohort
- Corporate Presentation - Biotech Investor Lunch
- Phase I Clinical Trial R327 Advances to 4000mg
- Phase I Positive Safety Data - 4000mg Complete
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals